We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+25.85%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.06B
AUM Growth
+$329M
Cap. Flow
-$217M
Cap. Flow %
-5.35%
Top 10 Hldgs %
37.39%
Holding
124
New
4
Increased
35
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$40.6M
2
GPCR icon
Structure Therapeutics
GPCR
+$16.4M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.8M
4
BPMC
Blueprint Medicines
BPMC
+$12.7M
5
IMVT icon
Immunovant
IMVT
+$12.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$84.9M
2
HUM icon
Humana
HUM
+$62.4M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.6M
4
ABCM
Abcam PLC
ABCM
+$28.9M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.98%
2 Consumer Staples 1.41%
3 Industrials 1.03%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AURA icon
101
Aura Biosciences
AURA
$796M
– –
-722,896
Closed -$6.48M
CRVO icon
102
CervoMed
CRVO
$26.5M
– –
-80,033
Closed -$370K
CYTK icon
103
Cytokinetics
CYTK
$10.5B
– –
-134,252
Closed -$3.96M
DSGN icon
104
Design Therapeutics
DSGN
$897M
– –
-460,391
Closed -$1.09M
FATE icon
105
Fate Therapeutics
FATE
$322M
– –
-612,215
Closed -$1.3M
HCAT icon
106
Health Catalyst
HCAT
$127M
– –
-307,500
Closed -$3.11M
NKTX icon
107
Nkarta
NKTX
$176M
– –
-331,571
Closed -$461K
SLRN
108
DELISTED
ACELYRIN
SLRN
– –
-141,876
Closed -$1.44M
SPRO icon
109
Spero Therapeutics
SPRO
$71.2M
– –
-57,373
Closed -$69.4K
SYRE icon
110
Spyre Therapeutics
SYRE
$9.29B
– –
-136,556
Closed -$1.67M
TPST icon
111
Tempest Therapeutics
TPST
$16.6M
– –
-41,247
Closed -$163K
XLV icon
112
State Street Health Care Select Sector SPDR ETF
XLV
$44B
– –
-200,000
Closed -$25.7M
GMDA
113
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-52,015
Closed -$53.6K
KNTE
114
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-405,811
Closed -$568K
BCEL
115
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-362,530
Closed -$94.6K
THRX
116
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-437,329
Closed -$1.18M
NVTA
117
DELISTED
Invitae Corporation
NVTA
– –
-585,659
Closed -$354K
SGEN
118
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-400,200
Closed -$84.9M
ABCM
119
DELISTED
Abcam PLC
ABCM
– –
-1,275,000
Closed -$28.9M
HZNP
120
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-255,500
Closed -$29.6M
1 2 3 4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Rock Springs Capital Management held 124 positions worth $4.06B, up 8.8% from $3.73B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Rock Springs Capital Management withdrew a net $217M in Q4 2023, closing 20 positions and reducing 29 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $84.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Eli Lilly worth $40.5M.

  • Rock Springs Capital Management's largest Q4 2023 buy was Eli Lilly: 69,500 shares worth $40.5M.
  • Rock Springs Capital Management added most to Celldex Therapeutics in Q4 2023, an estimated $13.8M increase.
  • Rock Springs Capital Management's biggest Q4 2023 reduction was Humana, cutting an estimated $62.4M.
  • Rock Springs Capital Management fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $84.9M.
  • Rock Springs Capital Management's ten largest holdings make up 37% of its $4.06B portfolio in Q4 2023.
  • Rock Springs Capital Management opened 4 new positions and closed 20 in Q4 2023.
  • Rock Springs Capital Management's portfolio value rose 8.8% quarter-over-quarter to $4.06B.

Based on Rock Springs Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.